Items where authors include "Venkitaraman, R"

Article

Howell, SJ, Casbard, A, Carucci, M et al. (14 more authors) (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology, 23 (7). pp. 851-864. ISSN 1470-2045

Dearnaley, D, Hinder, V, Hijab, A et al. (26 more authors) (2022) Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology. ISSN 1470-2045

Huddart, R, Hafeez, S, Lewis, R et al. (20 more authors) (2021) Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer. International Journal of Radiation: Oncology - Biology - Physics, 110 (2). pp. 412-424. ISSN 0360-3016

Proceedings Paper

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .